期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

熊去氧胆酸治疗原发性胆汁性肝硬化疗效观察 被引量：3

下载PDF
导出
摘要 目的采用熊去氧胆酸单独用药,以及与强的松或思美泰联合用药方法,观察三种治疗方案临床效果。方法29例分①熊去氧胆酸(尤思弗)组10例,给予尤思弗250mg,3/d,口服;②尤思弗+泼尼松组9例,上述剂量尤思弗加泼尼松,30mg/d,逐渐减量至10mg/d维持治疗;③尤思弗+思美泰组10例,上述剂量尤思弗加思美泰1.5g/d,静滴。4周为1个疗程,观察治疗后患者临床症状及肝功改善情况。结果治疗后三组患者乏力、纳差、皮肤瘙痒、尿黄、腹胀症状均有一定程度的缓解。泼尼松治疗组消化道症状及皮肤瘙痒症状缓解疗效较佳。三组退黄效果比较尤思弗与其他药物联合治疗组疗效相近,差异无统计学意义。结论单独使用尤思弗与联合药物治疗原发性胆汁性肝硬化疗效相近,且副作用少。而思美泰相对价格昂贵,限制了长期用药治疗。
作者 李华 赵红艳 赵军艳
机构地区 武警医学院附属医院消化内科
出处 《现代消化及介入诊疗》 2010年第1期50-51,共2页 Modern Interventional Diagnosis and Treatment in Gastroenterology
关键词 原发性胆汁性肝硬化 熊去氧胆酸 思美泰
分类号 R575.2 [医药卫生—消化系统]
  • 相关文献

参考文献4

  • 1Heathcote ELI. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology, 2000,31:1005-1013.
  • 2Beuers U. Hepatic overlap syndromes. J Hepatol, 2005,42(Suppl 1): S93-99.
  • 3顾波峰,姚定康,谢渭芬.原发性胆汁性肝硬化发病机制的研究进展[J].肝脏,2003,8(3):53-56. 被引量：22
  • 4Papatheodoridis GV, Hadziyannis ES, Deutsch M, et al. Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial. Am J Gastroenterol, 2002, 97:2063-2070.

二级参考文献21

  • 1Tanka A, Prindiville TP, Gish R, et al. Are infectious agents involved in primary billary cirrhosus? A PCR approach. J hepatol, 1999,31:664-671.
  • 2Gut J, Christen U, Frey N, et al. Molecular mimicry in halothene hepatitis: biochemical a structural characterization of lipoylated autoantigens. Toxicology, 1995,97:199-224.
  • 3Shimoda S, Nakamura M, Ishibashi H, et al. HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune disease. J Exp Med, 1995,181 : 1835-1845.
  • 4Shimoda S, Vae de Water J, Ansari A, et al. Identification and precursor frequency analys of a common T cell epitope motif in mitochondrial autoantigens in primary billary cirrhosis. J Clin Invest 1998;102:1831-1840.
  • 5Bandin O, Couvalin J, Poupon R, et al. Specificity and sensitivity of gp 210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary billary cirrhosis. Hrpatology 1996,23 : 1020-1024.
  • 6Wesierska-Gadek J, Honenauer H, Hitchman E, et al. Autoantibodies against nucleoporin p62 constitute a novel marker of primary billary cirrhosis. Gastroenterology, 1996,110:841-847.
  • 7Fussey SP, Ali ST, Guest JR, et al. Reactivity of primary billary cirrhosis sera with Escherichia coli dihydrolipoamide acetyltransferase(E2p) : characterization of the main immunodomint region. Proc Natl Acad Sci USA, 1990,87 : 3987-3991.
  • 8Stemerowicz R, Hopf U, Moiler B, et al. Are antimitochondrial antibodies in primary billary cirrhosis induced by R(rough)-mutants of enterobacteriaceae? Lancet, 1988,2 : 1166-1170.
  • 9Butler P, Valle F, Hamilton-Miller JM, et al. M2 antimitochondrialantibodiesand urinary rough mutant bacteria in patients with primary billary cirrhosis and in patients with recurrent bacteriurua. J Hepatol,1993,17:408-414.
  • 10Vilagut L, Vila L, Vinas O, et al. Cross reactivity of anti-Mycobacterium gornadae antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis. J Hepatol, 1994,21:673-677.

共引文献21

同被引文献14

引证文献3

二级引证文献11

现代消化及介入诊疗
2010年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部